What is the Real Measure of
Vitamin B12 Deficiency?

Revisiting the complexity of B12 deficiency

Vitamin B12 deficiency remains challenging because no single test can accurately diagnose or exclude deficiency in all clinical settings. Total serum B12 lacks sensitivity, and clinically meaningful (functional) deficiency can occur even when levels fall within the laboratory reference range.¹ This is particularly relevant in older adults, where cognitive decline, neuropathy, anaemia, and frailty may develop subtly and be mistaken for ageing.²

Risk factors for the development of vitamin B12 deficiency are common and often cumulative, including:

• Long-term proton pump inhibitor or H2-blocker therapy
• Metformin use
• Pernicious anaemia or autoimmune gastritis
• Older age, gastric atrophy and reduced intrinsic factor production³

Active B12: useful but far from perfect

Although Active B12 reflects the biologically available fraction of cobalamin, several practical and biological limitations should be acknowledged.

• Both serum vitamin B12 and holo-transcobalamin testing are characterised by a wide diagnostic “grey zone” that frequently necessitates confirmatory investigations and are significantly influenced by binding-protein biology.
• Active B12 measures cobalamin bound to transcobalamin II, the carrier protein responsible for cellular delivery, rather than serving as a direct marker of intracellular B12 activity.
• Transcobalamin II concentrations and receptor function are influenced by inflammation, liver and renal disease, ageing and genetic variation, such that holo-transcobalamin may appear normal or elevated despite impaired cellular utilisation, with documented cases demonstrating markedly elevated methylmalonic acid and homocysteine in the presence of normal serum and Active B12 levels.

A functional, clinically aligned pathway: reflex HCY testing

As methylmalonic acid is technically available under the MBS but requires specialised mass-spectrometry platforms and is not routinely accessible in many laboratories, and in response to the recent MBS changes aimed at improving identification of clinically significant (functional) vitamin B12 deficiency, our laboratory will implement reflex homocysteine (HCY) testing for all serum vitamin B12 results below 360 pmol/L, reframing this interval as “borderline” rather than “low-normal.”

This approach ensures that individuals at risk of early or functional deficiency, particularly older patients, receive additional biochemical clarification without the need for a separate test request or delays associated with referral MMA testing.

However, meaningful interpretation of HCY is essential:

• Mild elevations (16–20 μmol/L) are often non-specific and may reflect renal function, folate or B6 deficiency, or pre-analytical factors
• HCY >20 μmol/L correlates more strongly with clinically significant B12 deficiency and aligns with historic Active B12–based detection thresholds ^1,6

Reports will now include the updated interpretive comment:

“HCY is above the laboratory reference range, but values below 20 μmol/L are often non-specific and may not indicate clinically significant B12 deficiency. Levels >20 μmol/L are more consistent with vitamin B12 deficiency.”

Where does this leave GPs?

The inevitable question is: what is the real measure of B12 deficiency?

In practice, there is no single biochemical marker that answers this confidently. Clinical context, risk factors, and functional testing provide the most reliable pathway forward.

Our updated approach aims to: